Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA.

Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA.

BACKGROUND: The nature of free, uncomplexed prostate-specific antigen (PSA) in the circulation is still unknown. In this study, we developed novel anti-PSA antibodies using PSA produced by a metastasized cancer cell line, LNCaP, as an immunogen. METHODS: Hybridoma cell lines were screened with diffe...

Full description

Bibliographic Details
Main Authors:	Nurmikko, P, Väisänen, V, Piironen, T, Lindgren, S, Lilja, H, Pettersson, K
Format:	Journal article
Language:	English
Published:	2000

Similar Items

Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
by: Nurmikko, P, et al.
Published: (2002)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
by: Nurmikko, P, et al.
Published: (2001)

Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).
by: Peltola, M, et al.
Published: (2011)

Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
by: Sävblom, C, et al.
Published: (2009)

Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee.
by: Blijenberg, BG, et al.
Published: (2003)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
by: Törnblom, M, et al.
Published: (2001)

PSA is dead, long live PSA.
by: Vickers, A, et al.
Published: (2012)

Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age.
by: Sävblom, C, et al.
Published: (2005)

Lys chair.
by: Nur'Iffah Sa'adon.
Published: (2010)

Prostate cancer: estimating the benefits of PSA screening.
by: Vickers, A, et al.
Published: (2009)

Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer.
by: Lilja, H
Published: (2001)

Uji diagnostik prostate spesific antigen (PSA) pada keganasan prostat
by: , DAHESIHDEWI, Andaru, et al.
Published: (2002)

Erratum: Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level (British Journal of Urology International 87 (638-642))
by: Törnblom, M, et al.
Published: (2001)

Cleavage specificities of the brother and sister proteases Lys-C and Lys-N.
by: Raijmakers, R, et al.
Published: (2010)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
by: Steuber, T, et al.
Published: (2007)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
by: Denmeade, SR, et al.
Published: (2003)

Qualitative and quantitative PSA mRNA detection in prostate cancer - A useful tool for the clinician?
by: Phillips, J, et al.
Published: (2007)

Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms.
by: Végvári, A, et al.
Published: (2010)

Can PSA velocity predict risk of death in men with prostate cancer?
by: Lilja, H, et al.
Published: (2007)

Quantitative PSA RT-PCR for preoperative staging of prostate cancer.
by: Kurek, R, et al.
Published: (2003)

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.
by: Roddam, A, et al.
Published: (2005)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
by: Steuber, T, et al.
Published: (2006)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
by: O'Brien, M, et al.
Published: (2009)

We need a better marker for prostate cancer. How about renaming PSA?
by: Vickers, A, et al.
Published: (2012)

Pengaruh kateterisasi terhadap hasil penetapan prostate specific antigen (PSA) pada pasien gangguan prostat
by: Perpustakaan UGM, i-lib
Published: (2005)

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
by: Björk, T, et al.
Published: (2001)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
by: Olsson, A, et al.
Published: (2005)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
by: Haese, A, et al.
Published: (2001)

Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer.
by: Lilja, H
Published: (2008)

Lifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: Implications for epidemiological research
by: Littlejohns, T, et al.
Published: (2016)

Controversies in PSA screening
by: O'Sullivan, J
Published: (2017)

LysNDeNovo: an algorithm enabling de novo sequencing of Lys-N generated peptides fragmented by electron transfer dissociation.
by: van Breukelen, B, et al.
Published: (2010)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
by: Ulmert, D, et al.
Published: (2008)

Genetic correction of PSA values using sequence variants associated with PSA levels.
by: Gudmundsson, J, et al.
Published: (2010)

Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor.
by: Malm, J, et al.
Published: (2000)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
by: Becker, C, et al.
Published: (2001)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
by: Burton, A, et al.
Published: (2011)

PSA Kuasai Sirkit enam
by: Harian Metro,
Published: (2012)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)